Relevant bibliographies by topics / Fingolimod hydrochloride

Academic literature on the topic 'Fingolimod hydrochloride'

Author: Grafiati
Published: 22 June 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Fingolimod hydrochloride.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Contents

  1. Journal articles

Journal articles on the topic "Fingolimod hydrochloride":

1

Kaduk, James A., Kai Zhong, Amy M. Gindhart, and Thomas N. Blanton. "Crystal structure of fingolimod hydrochloride, C19H34ClNO2." Powder Diffraction 30, no. 3 (August 12, 2015): 205–10. http://dx.doi.org/10.1017/s0885715615000317.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
The crystal structure of fingolimod hydrochloride (C19H34ClNO2) has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Fingolimod hydrochloride crystallizes in space group P21/n (#14) with a = 7.137 53(5), b = 5.957 98(4), c = 49.5196(4) Å, β = 91.0808(7)°, V = 2105.46(2) Å3, and Z = 4. The structure consists of a “lipid bilayer” packing. The polar ends of the molecules make O–H···Cl and N–H···Cl hydrogen bonds to the chloride anion, and the octyl side chains pack adjacent to each other. The hydrogen bonds form three types of chains with graph sets C1,2(7), C1,2(7), and C1,2(8). The result is a complex chain of hydrogen bonds parallel to the b-axis. The powder pattern has been submitted to ICDD for inclusion in future releases of the Powder Diffraction File™.
2

Swain, Jitendriya, Santosh R. Borkar, Indrapal Singh Aidhen, and Ashok Kumar Mishra. "A molecular level understanding of interaction between FTY720 (Fingolimod hydrochloride) and DMPC multilamellar vesicles." RSC Adv. 4, no. 33 (2014): 17347–53. http://dx.doi.org/10.1039/c4ra02404d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
This work focuses on the molecular level understanding of interaction between FTY720 (Fingolimod hydrochloride) and dimyristoylphosphatidylcholine (DMPC) multilamellar vesicles (MLVs) as a drug molecule carrier by investigating the structural changes, solubilisation effect and thermotropic phase behaviour.
3

Ganhadeiro, Flaviane Maximino Bitencourt, Carla Resende Vaz Oliveira, and Bruno Cezario Costa Reis. "O benefício do uso de fingolimode em pacientes portadores de Esclerose Múltipla." Revista Eletrônica Acervo Médico 23, no. 4 (April 15, 2023): e12504. http://dx.doi.org/10.25248/reamed.e12504.2023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Objetivo: Avaliar os benefícios do uso de Fingolimode no tratamento do Esclerose Múltipla de acordo com cada faixa etária. Métodos: A parte metodológica é formada pelo National Library of Medicine, Biblioteca Virtual em Saúde e Directory of Open Access Journals que foram as bases de dados usadas para formar o compilado bibliográfico dessa revisão de literatura. Os descritores utilizados foram “Multiple Sclerosis”, “Drug Therapy” e “Fingolimod Hydrochloride”. Os critérios de inclusão foram artigos de ensaios clínicos, randomizados ou não randomizados, estudos de caso-controle, estudo de coorte, livre acesso, publicados em inglês, português, espanhol e no intervalo de 2018 a 2023. Resultados: Dos cinco artigos selecionados, foi relatado a redução das recidivas com o uso do Fingolimode, a melhor eficácia sustentada a longo prazo, melhor resultado no tratamento de pacientes afro-americanos com EM quando comparados aos outros e também que foi encontrado maior custo-efetividade no tratamento com Fingolimode quando comparado aos outros medicamentos. Considerações finais: Dessa forma, com o uso do Fingolimode relatam a redução das recidivas e também apresenta melhor eficácia sustentada a longo prazo. Além disso, a idade média abordada para esse tratamento é 37,5 anos.
4

Balasubramaniam, Sivaraman, Ganapathy Sankaran, and Sneh Badle. "Perspective on FTY720, an Immunosuppressant." Synthesis 50, no. 05 (January 24, 2018): 968–83. http://dx.doi.org/10.1055/s-0036-1591877.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
FTY720 {fingolimod hydrochloride, 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride}, a novel immunosuppressant, was discovered by chemical modification based on the structure activity relationships of ISP-I (myriocin), a metabolite of the fungus Isaria­ sinclairii. This short perspective provides insights to the various strategies available in the literature for the synthesis of FTY720 and its analogues.1 Introduction2 Classification of Immunosuppressive Drugs3 The Rise of FTY7204 Different Synthetic Strategies for FTY7205 Analogues of FTY7206 Binding Studies of FTY7207 Mode of Action8 Conclusion
5

Hussar, Daniel A., and David E. Zimmerman. "New drugs: Dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate." Journal of the American Pharmacists Association 51, no. 1 (January 2011): 122–26. http://dx.doi.org/10.1331/japha.2011.11506.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vinigari, Krishna, Krishna Jonnada, Noorjahan Mohammed, and Girija Mangatayaru Kotu. "An alternative efficient approach for the synthesis of Fingolimod hydrochloride." Synthetic Communications 49, no. 1 (January 2, 2019): 39–48. http://dx.doi.org/10.1080/00397911.2018.1536788.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thomas, Katja, Undine Proschmann, and Tjalf Ziemssen. "Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis." Expert Opinion on Pharmacotherapy 18, no. 15 (September 4, 2017): 1649–60. http://dx.doi.org/10.1080/14656566.2017.1373093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ward, Melanie D., David E. Jones, and Myla D. Goldman. "Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis." Expert Opinion on Drug Safety 13, no. 7 (June 16, 2014): 989–98. http://dx.doi.org/10.1517/14740338.2014.920820.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tamakuwala, Mayurkumar, Warren Ratna, Amit Joshi, and Grazia Stagni. "Fingolimod hydrochloride gel shows promising therapeutic effects in a mouse model of atopic dermatitis." Journal of Pharmacy and Pharmacology 68, no. 10 (July 27, 2016): 1268–77. http://dx.doi.org/10.1111/jphp.12588.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Suresh Kumar, Ramdoss, Hariram Balasubramanian, Kalyanaraman Lakshminarayanan, Srinivasu K. Mullapudi, Katkam Srinivas, and Rajeswar Reddy Sagyam. "A systematic approach for reversed phase liquid chromatographic method development of fingolimod hydrochloride via design augmentation." Arabian Journal of Chemistry 12, no. 8 (December 2019): 3289–301. http://dx.doi.org/10.1016/j.arabjc.2015.08.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Fingolimod hydrochloride' for particular source types:
Journal articles

To the bibliography